FDA chief admits he oversold COVID-19 plasma effectiveness


Scientists were immediately skeptical when Food and Drug Administration chief Stephen Hahn, Health Secretary Alex Azar, and President Trump announced Sunday evening that the FDA had given emergency use approval for plasma from recovered COVID-19 patients, right before the Republican National Convention. And they were baffled when all three men claimed plasma had been shown to reduce deaths by 35 percent, meaning, Hanh said, that 35 out of 100 COVID-19 patients "would have been saved because of the administration of plasma."
That impressive statistic was evidently excavated from a small subsample of a large observational study from the Mayo Clinic, and it doesn't mean what Trump, Azar, and Hahn said it does. Hahn and whoever else came up with the number "appeared to have mixed up absolute risk and relative risk, which are basic concepts in economics and in the presentation of data from clinical trials," The Washington Post notes, explaining:
Essentially, the Trump administration figures had compared one group of patients who got a certain kind of plasma with a group who got a different concentration at a different point in the disease, thus showing the relative difference between those groups. It was not a measure of what happens when some patients get plasma and some don't — the kind of research necessary to send a signal of whether a treatment is truly helping. The FDA also considered data from other studies. [The Washington Post]
After facing criticism from incredulous medical scientists, Hanh acknowledged his error:
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Scientists have reasonable hopes that convalescent plasma, a century-old treatment, will be effective at helping COVID-19 patients recover, at least until a reliable treatment is found or developed. But so far the evidence is "still very low-quality" and "not conclusive, World Health Organization chief scientist Dr. Soumya Swaminathan cautioned Monday.
It isn't really the exaggeration of plasma's benefits that worry medical experts, The New York Times reports. It's that, given how "Trump has appeared to politicize the process of approving treatments and vaccines for the coronavirus," nobody will believe "the scientific judgment of the FDA" when it says a vaccine is safe and effective.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
The Week Unwrapped: How did Japan become a space superpower?
Podcast Plus, why on earth are Labubu dolls so popular? Will buy-now-pay-later cause a new financial crisis?
-
The week's best photos
In Pictures A tomato fight, painting behind bars, and more
-
Mountainhead: Jesse Armstrong's tech bro satire sparkles with 'weapons-grade zingers'
The Week Recommends The Succession creator's first feature film lacks the hit TV show's 'dramatic richness' – but makes for a horribly gripping watch
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows